letrozole has been researched along with Benign Neoplasms, Brain in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 8.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| " Here, we investigated the pharmacokinetics of letrozole, a third-generation aromatase inhibitor, in the normal brain and in orthotopically implanted C6 glioma in Sprague-Dawley rats." | 7.79 | The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. ( Dave, N; Desai, PB; Gudelsky, GA, 2013) |
| "Letrozole has demonstrated efficacy in pre-clinical GBM models." | 5.62 | Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. ( Amarh, E; Assiri, AA; Dave, N; Overholser, BR; Pollok, KE; Shugg, T, 2021) |
| "Brain metastases from breast cancer have a poor prognosis." | 5.33 | Letrozole for brain and scalp metastases from breast cancer--a case report. ( Bhatt, ML; Kirti, S; Kumar, S; Madhup, R; Srivastava, M; Srivastava, PK, 2006) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 4.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "The aromatase inhibitor, letrozole, is being investigated in experimental animal models as a novel treatment for high-grade gliomas (HGGs)." | 3.91 | Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ( Adams, CH; Arora, P; DasGupta, B; Desai, PB; Gudelsky, G, 2019) |
| " Here, we investigated the pharmacokinetics of letrozole, a third-generation aromatase inhibitor, in the normal brain and in orthotopically implanted C6 glioma in Sprague-Dawley rats." | 3.79 | The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. ( Dave, N; Desai, PB; Gudelsky, GA, 2013) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "Letrozole has demonstrated efficacy in pre-clinical GBM models." | 1.62 | Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma. ( Amarh, E; Assiri, AA; Dave, N; Overholser, BR; Pollok, KE; Shugg, T, 2021) |
| "Seventy-two patients with breast cancer who failed chemotherapy were treated at the Tumor Hospital of Harbin Medical University from January 2001 to January 2012." | 1.39 | [Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy]. ( Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP, 2013) |
| "Brain metastases from breast cancer have a poor prognosis." | 1.33 | Letrozole for brain and scalp metastases from breast cancer--a case report. ( Bhatt, ML; Kirti, S; Kumar, S; Madhup, R; Srivastava, M; Srivastava, PK, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Karve, AS | 1 |
| Desai, JM | 1 |
| Dave, N | 3 |
| Wise-Draper, TM | 1 |
| Gudelsky, GA | 2 |
| Phoenix, TN | 1 |
| DasGupta, B | 2 |
| Sengupta, S | 1 |
| Plas, DR | 1 |
| Desai, PB | 3 |
| Acar Çevik, U | 1 |
| Kaya Çavuşoğlu, B | 1 |
| Sağlık, BN | 1 |
| Osmaniye, D | 1 |
| Levent, S | 1 |
| Ilgın, S | 1 |
| Özkay, Y | 1 |
| Kaplancıklı, ZA | 1 |
| Shugg, T | 1 |
| Amarh, E | 1 |
| Assiri, AA | 1 |
| Pollok, KE | 1 |
| Overholser, BR | 1 |
| Arora, P | 1 |
| Adams, CH | 1 |
| Gudelsky, G | 1 |
| Nie, D | 1 |
| You, QS | 1 |
| Luan, JW | 1 |
| Li, Y | 1 |
| Li, XL | 1 |
| Guo, RT | 1 |
| Zhang, LP | 1 |
| Wu, J | 1 |
| Tivnan, A | 1 |
| Heilinger, T | 1 |
| Ramsey, JM | 1 |
| O'Connor, G | 1 |
| Pokorny, JL | 1 |
| Sarkaria, JN | 1 |
| Stringer, BW | 1 |
| Day, BW | 1 |
| Boyd, AW | 1 |
| Kim, EL | 1 |
| Lode, HN | 1 |
| Cryan, SA | 1 |
| Prehn, JH | 1 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Arnould, L | 1 |
| Fumoleau, P | 1 |
| Madhup, R | 1 |
| Kirti, S | 1 |
| Bhatt, ML | 1 |
| Srivastava, PK | 1 |
| Srivastava, M | 1 |
| Kumar, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for letrozole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
8 other studies available for letrozole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Benzimidazoles; Brain Neoplasms; Cell Proliferation; Ce | 2020 |
Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.
Topics: Androstadienes; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Ether-A-Go-Go P | 2021 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis.
Topics: Algorithms; Animals; Antineoplastic Agents; Area Under Curve; Brain; Brain Neoplasms; Chromatography | 2013 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms | 2013 |
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tum | 2017 |
Letrozole for brain and scalp metastases from breast cancer--a case report.
Topics: Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Le | 2006 |